文献速递核素与放射性配体治疗放射性药物与辐射防护

177Lu-DOTATATE靶向放疗后患者剂量学的临床实践实施

Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate.
PubMed 文献 · EJNMMI Res · 2018-11-29

本研究旨在利用商用工作站开发剂量学方法,用于177Lu肽受体放射性核素治疗(PRRT)中危及器官的常规评估。通过体模确定平面和SPECT灵敏度因子、优化重建参数并计算恢复系数,随后对12例神经内分泌肿瘤患者进行SPECT/CT采集,计算肝脏、脾脏、肾脏和红骨髓的每单位给药活度剂量(AD/A admin)。结果显示所得AD/A admin值与文献数据一致,且使用个性化器官质量与标准器官质量计算时差异显著,表明临床实践中患者剂量学的技术可行性及获取患者特异性信息的必要性。

要点

  • 平面和SPECT/CT采集的灵敏度因子分别为6.11 ± 0.01和5.67 ± 0.08 counts/s/MBq。
  • 肾脏、肝脏、脾脏和红骨髓的平均AD/A admin分别为0.43 ± 0.13、0.54 ± 0.58、0.61 ± 0.13和0.04 ± 0.02 mGy/MBq。
  • 使用个性化与标准器官质量计算的AD/A admin值在肾脏(p = 1 × 10-7)、脾脏(p = 0.0069)和红骨髓(p = 0.0027)中差异显著。

核心结论

  • 获得的AD/A admin值与文献数据一致,表明临床实践中患者剂量学技术可行。
  • 研究显示需要获取患者特异性信息以优化剂量学评估。

研究设计与样本

  • 在体模上确定平面和SPECT灵敏度因子,优化SPECT/CT重建参数,并在多种体模上确定恢复系数。
  • 对12例接受177Lu-DOTATATE PRRT的神经内分泌肿瘤患者,在注射后4、24、72和192小时采集SPECT/CT图像。
  • 使用OSEM方法重建SPECT数据,采用MIRD形式主义和OLINDA/EXM软件计算器官剂量。

主要发现

  • 平面和SPECT/CT采集的灵敏度因子分别为6.11 ± 0.01和5.67 ± 0.08 counts/s/MBq。
  • 模拟L2-L4红骨髓的恢复系数为0.78。
  • 肾脏、肝脏、脾脏和红骨髓的平均AD/A admin分别为0.43 ± 0.13 mGy/MBq [0.27-0.91]、0.54 ± 0.58 mGy/MBq [0.12-2.26]、0.61 ± 0.13 mGy/MBq [0.42-0.89]和0.04 ± 0.02 mGy/MBq [0.01-0.09]。
  • 使用个性化与标准器官质量计算的AD/A admin值在肾脏(p = 1 × 10-7)、脾脏(p = 0.0069)和红骨髓(p = 0.0027)中差异显著。
  • 在靠近或包含肿瘤细胞或转移灶的器官中观察到患者内差异。

关键数值与推荐

  • SPECT数据重建使用OSEM方法,6次迭代和10个子集,并应用衰减、散射、恢复分辨率校正及0.11 cm高斯后滤波。
  • 剂量计算采用MIRD形式主义和驻留时间(Dosimetry toolkit®应用),使用标准及基于CT成像的器官质量(OLINDA/EXM® V1.0软件)。

临床怎么用

  • 本方法可用于177Lu PRRT临床实践中对危及器官的常规剂量学评估。
  • 建议使用患者特异性器官质量以提高剂量学评估的准确性。

局限性

  • 研究样本量较小(12例患者),可能影响结果的普遍性。
  • 原文未报告其他潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study's aim was to develop our dosimetric methodology using a commercial workstation for the routine evaluation of the organs at risk during peptide receptor radionuclide therapy (PRRT) with 177Lu. METHODS: First, planar and SPECT sensitivity factors were determined on phantoms. The reconstruction parameters were optimized by SPECT/CT image acquisition using a NEMA IEC phantom containing a 500 ml bottle of 177Lu, to simulate a kidney. The recovery coefficients were determined on various phantoms. For the red marrow, this was calculated using a NEMA IEC phantom that contained a centrally placed bottle of 80 ml of 177Lu (to model the L2-L4 red marrow) flanked by two 200 ml bottles with 177Lu to simulate the kidneys. Then, SPECT/CT images were acquired at 4, 24, 72, and 192 h after injection in 12 patients with neuroendocrine tumors who underwent PRRT with 177Lu-DOTATATE. SPECT data were reconstructed using the iterative ordered subset expectation maximization (OSEM) method, with six iterations and ten subsets, attenuation, scatter, recovery resolution corrections, and a Gaussian post-filter of 0.11 cm. The liver, spleen, kidneys, and red marrow dose per administered activity (AD/A admin) values were calculated with the Medical Internal Radiation Dose (MIRD) formalism and the residence times (Dosimetry toolkit® application) using standard and CT imaging-based organ masses (OLINDA/EXM® V1.0 software). RESULTS: Sensitivity factors of 6.11 ± 0.01 and 5.67 ± 0.08 counts/s/MBq were obtained with planar and SPECT/CT acquisitions, respectively. A recovery coefficient of 0.78 was obtained for the modeled L2-L4 red marrow. The mean AD/A admin values were 0.43 ± 0.13 mGy/MBq [0.27-0.91] for kidneys, 0.54 ± 0.58 mGy/MBq [0.12-2.26] for liver, 0.61 ± 0.13 mGy/MBq [0.42-0.89] for spleen, and 0.04 ± 0.02 mGy/MBq [0.01-0.09] for red marrow. The AD/A admin values varied when calculated using the personalized and standard organ mass, particularly for kidneys (p = 1 × 10-7), spleen (p = 0.0069), and red marrow (p = 0.0027). Intra-patient differences were observed especially in organs close to or including tumor cells or metastases. CONCLUSIONS: The obtained AD/A admin values were in agreement with the literature data. This study shows the technical feasibility of patient dosimetry in clinical practice and the need to obtain patient-specific information.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Santoro L, Mora-Ramirez E, Trauchessec D, et al. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Res. 2018. PMID: 30498938. doi:10.1186/s13550-018-0459-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。